Clinical studies have shown improved outcomes with anti-VEGF and adjuvant renin-angiotensin system (RAS) inhibitors across tumor types, including glioblastoma, renal cell carcinoma, hepatocellular carcinoma, and metastatic colorectal carcinoma (206–210). Here, VEGFA is linked to neoplasm.